## FORM 4

# **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington,	D.C.	20549
vvasiliigion,	D.C.	20040

# STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL							
OMB Number:	3235-0287						
Estimated average burder	n						
hours per response.	0.5						

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     Hingtgen Tim				<u>C</u>	2. Issuer Name and Ticker or Trading Symbol COMMUNITY HEALTH SYSTEMS INC								Relationship of Reporting Person(s) to Issuer (Check all applicable)     X Director 10% Owner									
					-   -	СҮН ]									Y Officer (give title Other (specify							
(Last) (First) (Middle)					3.	Date	of Earliest	Transac	tion (Mo	onth/Da	ay/Year)		$\dashv$		below)	C	EO	below)				
4000 MERIDIAN BOULEVARD						3/01/			,		,											
(Street) FRANKLIN TN 37067				4.	4. If Amendment, Date of Original Filed (Month/Day/Year)									Individual or Joint/Group Filing (Check Applicable Line)     X Form filed by One Reporting Person     Form filed by More than One Reporting Person								
(City) (State) (Zip)					-																	
(City)	(30																					
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned  1. Title of Security (Instr. 3)  2. Transaction 2A. Deemed 3. 4. Securities Acquired (A) or 5. Amount of 6. Ownership 7. Nature of																						
1. Title of Security (Instr. 3)				2. Transaction Date (Month/Day/Year)			2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 ar			nd 5) Securities Beneficial Following			Form:	Direct Indirect Itr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
								Code	v	Amount	(A) or (D)	Price		Reported Transaction(s) (Instr. 3 and 4)								
Common S	Stock			03/0	)1/20	21			M		150,000 <sup>(1)</sup> A		\$0.0	00	516,1	31		D				
Common S	Stock			03/0	)1/20	21			A		100,000	A	\$0.00	0(2)	616,131		D					
Common S	Stock			03/0	)2/20	21			F		86,081	D	\$8.8	31	530,0	50	50 D					
			Table II -								sed of, o			Ow	ned							
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Da if any (Month/Day/Y	ite, Ti	l. Transa Code (I	ction	5. Number Derivative Securities Acquired Disposed (Instr. 3, 4	ber of ve Expiration Date (Month/Day/Year) do of (D)			sable and te	7. Title and of Securit Underlying Derivative (Instr. 3 and	d Amouries g Securit		8. Price of Derivative Security (Instr. 5)	9. Numbe derivative Securities Beneficia Owned Following	e Ownersh es Form: Direct (D or Indire g (I) (Instr.	Ownership	Beneficial Ownership t (Instr. 4)			
				С	Code	v	(A)	(D)	Date Exercisable		Expiration Date	Title	Amour or Number of Sha	er		Reported Transaction(s) (Instr. 4)						
Performance Based Restricted	\$0.00	03/01/2021			M			75,000	(1)		(1)	Common Stock	75,0	00	\$0.00	0		D				
Performance Based Restricted	\$0.00	03/01/2021			A		200,000		(3)		(3)	Common Stock	200,0	000	\$0.00	50.00 200,		D				
Stock Options (Right to Buy)	\$8.81	03/01/2021			Α		100,000		03/01/2	2022 <sup>(4)</sup>	02/28/2031	Common Stock	100,0	000	\$0.00	100,000		D				
Performance Based Restricted	\$0.00								(5	5)	(5)	Common Stock	112,5	00		112,500		D				
Performance Based Restricted	\$0.00								(6	5)	(6)	Common Stock	150,0	000		150,000		D				
Stock Options (Right to Buy)	\$17.49								02/16/	/2013	02/15/2022	Common Stock	334	4		334		D				
Stock Options (Right to Buy)	\$4.99								03/01/	/2020	02/28/2029	Common Stock	56,2:	50		56,2	50	D				
Stock Options (Right to Buy)	\$4.93								03/01/	/2021	02/28/2030	Common Stock	75,00	00		75,000		D				
Stock Options (Right to Buy)	\$4.93			T					03/01/	/2021	02/28/2030	Common Stock	200,0	000		200,000		D				

#### Explanation of Responses:

- 1. The vesting of these performance-based restricted shares was based on the attainment of certain performance objectives between 1/1/2018 and 12/31/2020 (the "2018-2020 Performance Period"). Based on the actual level of achievement of such performance objectives for the 2018-2020 Performance Period, the award vested on March 1, 2021 at 200% of the target number of the performance-based restricted shares originally reported by the reporting person on 3/2/2018.
- 2. The time-vesting restrictions on this award of restricted stock will lapse in 1/3 increments on the first, second and third anniversary of the date of grant.
- 3. The vesting of these performance-based restricted shares is allocated to the attainment of the following pre-determined performance objectives between 1/1/2021 and 12/31/2023 (the "2021-2023 Performance Period"), as follows: 40% to a Cumulative Consolidated Adjusted EBITDA Growth target; 40% to a Cumulative Same-Store Net Revenue Growth target; and 20% to a Total Shareholder Return ("TSR") Percentile Rank target. The target number (100%) of the total performance-based restricted shares is reported in the table set forth above. Between 0% and 200% of the portion of the target number of performance-based restricted shares allocated to each performance objective will ultimately vest on the third anniversary of the date of grant, subject to the attainment of the applicable performance objective, with the vesting percentage to be determined based upon the level of achievement with respect to the applicable performance objective during the 2021-2023 Performance Period.
- 4. Vesting occurs in 1/3 increments on the first, second and third anniversary of the date of grant.
- 5. The vesting of these performance-based restricted shares is subject to the attainment of certain performance objectives between 1/1/2019 and 12/31/2021 (the "2019-2021 Performance Period"). The target number (100%) of the total performance-based restricted shares is reported in the table set forth above. Between 0% and 200% of the portion of the target number of performance-based restricted shares allocated to each applicable performance objective will ultimately vest on the third anniversary of the date of grant, subject to the attainment of the applicable performance objective, with the vesting percentage to be determined based upon the level of achievement with respect to the applicable performance Period.
- 6. The vesting of these performance-based restricted shares is subject to the attainment of certain performance objectives between 1/1/2020 and 12/31/2022 (the "2020-2022 Performance Period"). The target number (100%) of the total performance-based restricted shares is reported in the table set forth above. Between 0% and 200% of the portion of the target number of performance-based restricted shares allocated to each

applicable performance objective will ultimately vest on the third anniversary of the date of grant, subject to the attainment of the applicable performance objective, with the vesting percentage to be determined based upon the level of achievement with respect to the applicable performance objective during the 2020-2022 Performance Period.

### Remarks:

<u>Christopher G. Cobb, Attorney in</u> <u>03/02/2021</u> <u>Fact for Tim Hingtgen</u>

\*\* Signature of Reporting Person Dat

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.